论文部分内容阅读
从双鹤1997年刚刚上市时2.36亿的销售额,到2001年的23.8亿元,年均73％的增速令人瞩目。今年一季度,北京双鹤药业完成了8.15亿元的销售额,为全年超过40亿元的目标打下了基础。在双鹤迅速膨胀的过程中,通过资本运作,其苦心缔造的“大输液帝国”功不可没。在2001年完成了3.6亿瓶大输液产品的销售,这一相当于整个欧洲的销量,使双鹤目前已经称得上是世界最大的输液产品制造商。不过和欧美的输液企业相比,无论在技术实力还是在生产率方面,双鹤都算不上强者。但从大到强的欲望,使双鹤决定要在今明两年内收购5～8家欧美以及亚太的厂商。而要成为一家跨国公司,双鹤对信息化的需求非常强烈。
From the sale of 236 million yuan to the 2.83 billion yuan that was just listed in 1997, the average annual growth rate of 73% was impressive. In the first quarter of this year, Beijing Shuanghe Pharmaceutical completed sales of RMB 815 million, laying the foundation for the goal of more than RMB 4 billion for the whole year. In the process of the rapid expansion of the Double Crane, through the capital operation, the “big infusion empire” painstakingly created contributed to it. In 2001, the sale of 360 million bottles of infusion products was completed. This is equivalent to sales in Europe, making Shuanghe the world’s largest infusion product manufacturer. However, compared with the infusion companies in Europe and the United States, both the technical strength and productivity, the double crane is not strong. However, the desire to become stronger led Shuanghe to decide to acquire 5-8 suppliers in Europe, America and Asia Pacific in the next two years. To become a multinational company, Shuanghe’s demand for information technology is very strong.